The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[6]Injection site reactions were also common, reported in 3% of subjects.[8]
Bimekizumab was approved for medical use in the European Union in August 2021,[6][9][10] and in the United States in October 2023.[11][12]
Medical uses
In the EU, bimekizumab is
indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.[6]
History
Bimekizumab is being developed by Belgian pharmaceutical company
UCB.[citation needed]
^World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3).
hdl:10665/331112.
^Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. (February 2021). "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial". Lancet. 397 (10273): 487–498.
doi:
10.1016/S0140-6736(21)00125-2.
PMID33549193.
S2CID231809826.
Further reading
Reis J, Vender R, Torres T (August 2019). "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis". BioDrugs. 33 (4): 391–399.
doi:
10.1007/s40259-019-00361-6.
PMID31172372.
S2CID174812750.